Eastgate Biotech Corp.
Eastgate Biotech Corp.
Your view on ETBI
Overview
What the company does, where it operates, and who runs it.
About Eastgate Biotech Corp.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Rosella C. Perri
- Headquarters
- 65 Harbour Square Suite 2203Toronto, M5J 2L4Canada, Toronto, NV, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Rosella C. Perri
- Headquarters
- 65 Harbour Square Suite 2203Toronto, M5J 2L4Canada, Toronto, NV, US
EastGate Biotech Corp. is a pharmaceutical company. The Company produces and distributes nutraceuticals that are based on natural therapies and absorbed naturally by the body.
It utilizes state-of-the-art nanotechnologies to deliver healthy alternatives to conventional pharmaceuticals that all too often create dangerous side effects and unexpected consequences for those trying to attain and maintain healthy lives. The Company’s products include E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze and Warts X.
The Company develops products in which the components are incorporated into vehicles containing nano-sized delivery vectors, including oil droplets (nanoemulsions), polymeric particles (nanoparticles) and the combination of polymers and lipids with surfactants (hybrid nanoparticles, nanocapsules, mixed micelles).
It has its offices in New York, London SF, Cockfosters BP, Los Angeles, Chicago and Las Vegas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Eastgate Biotech Corp., and the rating behind it. ETBI last traded at $0.0010; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Eastgate Biotech Corp.. Starting points for Eastgate Biotech Corp.: beta 3.42 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Eastgate Biotech Corp.. Eastgate Biotech Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Eastgate Biotech Corp.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Eastgate Biotech Corp.. Eastgate Biotech Corp. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Eastgate Biotech Corp. valued side by side against its closest peers. Eastgate Biotech Corp. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Eastgate Biotech Corp., and how their positions are changing. At a $2.1M market value, institutional positions materially move Eastgate Biotech Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Eastgate Biotech Corp. executives and directors. Shares of Eastgate Biotech Corp. have traded between $0.0001 and $0.0045 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Eastgate Biotech Corp.. Eastgate Biotech Corp. is a $2.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Eastgate Biotech Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Eastgate Biotech Corp.. Coverage tracks Eastgate Biotech Corp. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.